Functional signaling of membrane-bound TL1A induces IFN-γ expression  by Biener-Ramanujan, Eva et al.
FEBS Letters 584 (2010) 2376–2380journal homepage: www.FEBSLetters .orgFunctional signaling of membrane-bound TL1A induces IFN-c expression
Eva Biener-Ramanujan, Rivkah Gonsky, Brian Ko, Stephan R. Targan *
Inﬂammatory Bowel Disease Center and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, United Statesa r t i c l e i n f o
Article history:
Received 22 February 2010
Revised 8 April 2010
Accepted 12 April 2010
Available online 18 April 2010
Edited by Beat Imhof
Keywords:
TL1A signaling
Membrane-bound TL1A
Death domain receptor 3
IFN-c0014-5793/$36.00  2010 Federation of European Bio
doi:10.1016/j.febslet.2010.04.030
* Corresponding author.
E-mail address: targans@cshs.org (S.R. Targan).a b s t r a c t
TL1A, a TNF member implicated in autoimmune diseases, is a transmembrane protein that is pro-
cessed to release soluble TL1A (TL1A-S). TL1A-S induces a Th1 response, although the functional sig-
niﬁcance of membrane-bound TL1A (TL1A-M) remains unknown. We generated TL1A-M expression
in HEK-293 cells capable of binding DR3-Fc. Co-incubating IL-12/IL-18-primed CD4+ T cells with HEK-
293 cells expressing TL1A-M induced 3-fold increase in IFN-c that was blocked by anti-TL1A Ab.
These results demonstrate that TL1A-M can bind death domain receptor 3 (DR3) through cell–cell
contact to induce downstream IFN-c secretion enhancement. Anti-TL1A antibodies designed to treat
immune diseases should be veriﬁed to block both endogenous TL1A forms.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
TL1A is a tumor necrosis factor (TNF) family member [1]. TL1A
has been directly implicated in autoimmune disease pathogenesis
such as rheumatoid arthritis [2–4], autoimmune encephalomyelitis
[5,6], asthma [7] and inﬂammatory bowel disease [8,9]. TL1A was
ﬁrst reported to be expressed exclusively in human endothelial
cells in response to TNFa or IL-1 [1]. Recent reports demonstrated
inducible TL1A expression in macrophages [10,11], T cells [12,13],
monocytes and dendritic cells [14–17]. TL1A is synthesized as a 28-
kDa type II membrane protein with an extracellular domain that
contains the TNF homology domain (THD) (Fig. 1A). THD can bind
death domain receptor 3 (DR3), a TNF receptor (TNFR) family
member, and induce signaling. TL1A can also bind to TR6/DcR3, a
soluble decoy receptor that serves as negative regulator.
Membrane-bound TL1A (TL1A-M) can be processed to release a
20-kDa soluble TL1A (TL1A-S) [1]. The identity of the protease
responsible for TL1A processing is not yet known but possibly be-
longs to the matrix metalloproteinase family.
Although most TNF family ligands occur as both transmem-
brane and soluble forms, some are more functionally active in their
membrane form (FASL) [18], some as soluble form (EDA [19,20]
and APRIL) [21], and some in both forms (BAFF) [22]. TL1A-S has
been shown to induce functional consequence when expressed
by immune complex (IC)-induced monocytes [16] or when added
in recombinant form [1,12,13]. However, it is not clear whether
TL1A can act through its membrane-bound form via cell–cell con-chemical Societies. Published by Etact. Recent studies suggest that expression of the two forms of
TL1A is differentially regulated by the different cells. Monocytes
and dendritic cells were shown to express both TL1A-M and
TL1A-S in response to IC [15,16] or microbial organisms stimuli
[17]. IC did not induce TL1A-S expression in lymphocytes [16].
Conversely, inducible expression of TL1A was observed only at
the membrane level of T cells [12] but not in the cultured media
(Gonsky and Deem, unpublished results). CCR9+CD4+ T cells were
found to constitutively express TL1A-M [13]. In these reports,
TL1A expression was shown to augment IL-12/IL-18-mediated
IFN-c production. However, it is not known if enhanced IFN-c pro-
duction could be attributed to TL1A-S or TL1A-M.
To address this question we engineered a construct expressing a
non-cleavable TL1A-M and demonstrated that TL1A-M binds DR3
and enhances IFN-c production in primed CD4+ T cells. Our data
imply that TL1A can function as membrane-bound protein and in-
duce signaling through cell–cell contact.
2. Materials and methods
2.1. Preparation of Flag-tagged TL1A (A71D), TL1A (D66–75) and TL1A
(D66–94)
To prepare full-length TL1A (TL1A-FL) expression vector, Flag-
tagged upstream (pFlag-TL1A-FL), TL1A-FL sequence was PCR
ampliﬁed from a pcDNA3.1-TL1A (Teva Pharmaceuticals) using
the primers 50-aaaaagcttatggccgaggatctgggactgag-30 (forward)
and 50-aaaggatccctagagtaagaaggctccaaagaaggt-30 (reverse). TL1A-S
(aa61–251) from pCMV1-Flag-TL1A-S (Teva Pharmaceuticals) was
removed following HindIII/BamHI digestion and replaced withlsevier B.V. All rights reserved.
Fig. 1. Schematic diagram of modiﬁcations in TL1A. FL, full length; TM, transmem-
brane; TL1A-S, soluble form of TL1A; PPT, preprotrypsin; TL1A-M, non-cleavable
form of TL1A.
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from pFlag-TL1A-FL by site directed mutagenesis using the primers
50-cgtcagaattaattcaccatg-30 (forward) and 50-gtcgtcatcgtctttgtagtc-
30 (reverse). To prepare TL1A-FL expression vector, Flag-tagged
downstream (pTL1A-FL-Flag), TL1A-FL sequence was PCR ampliﬁed
from pCDNA3.1-TL1A, using the primers 50-aaagaattcatggccgaggat-
ctgggactgag-30 (forward) and 50-aaactcgagtaagaaggctccaaagaaggt-
30 (reverse), and inserted into pIRES-hrGFP-1a (Stratagene Santa
Clara, CA). TL1A(A71D), TL1A(D66–75) and TL1A(D66–94) expres-
sion vectors were generated by mutating pFlag-TL1A-FL and
pTL1A-FL-Flag expression vectors using the primers 50-gag-
gcctgtgtgcagttccaagatctaaaaggacagg-30 (forward) and 50-
cctgtccttttagatcttggaactgcacacaggcctc-30 (reverse) for Ala71 to
Asp substitution, 50-cccagggagaggccgagtttgcaccttc-30 (forward)
and 50-gaaggtgcaaactcggcctctccctggg-30 (reverse) for aa66–75 dele-
tion and 50-ccagggagaggccccaagggcacacc-30 (forward) and 50-
ggtgtgcccttggggcctctccctgg-30 (reverse) for aa66–94 deletion. All
constructs were veriﬁed by digestion and sequencing.
2.2. Immunoblotting and DR3 binding assay
HEK-293 cells were obtained from and cultured as recom-
mended by the American Tissue Culture Collection. Cells were
transfected with TL1A-FL, TL1A-M, TL1A-S expression vectors or
mock transfected with pIRES-hrGFP using effectene transfection
reagent (Qiagen, Valencia, CA) according to the manufacturer’s
instructions. Twenty-four hours post-transfection cells and super-
natants were collected, and cells were lysed in 0.5 ml RIPA buffer
(Cell Signaling, Beverly, MA). For DR3 binding assay cell lysates
were incubated with 3 lg recombinant DR3-Fc (Alexis Biochemi-
cals, San Diego, CA) at 4 C for an hour followed by addition of
20 ll true-blot beads (eBioscience, San Diego, CA) and incubated
at 4 C with rotation, overnight. Beads were washed thoroughly
and boiled in reducing sample buffer to elute precipitated proteins.
Protein samples were separated on 10% or 15% SDS–PAGE and
immunoblotted with monoclonal anti-Flag (Sigma, St. Louis, MO),
or monoclonal anti- hTL1A Abs (04H08, 16H02) (Teva Pharmaceu-
ticals) followed by IRDye 680 goat anti-mouse Ab (LI-COR Biosci-
ences, Lincoln, NE). Membranes were imaged using the Odyssey
infrared imaging system (LI-COR Biosciences).
2.3. Immunoﬂuorescence
HEK-293 cells, plated on poly-D-lysine treated coverslips, were
transfected with TL1A-FL, TL1A-M or TL1A-S expression vectors.
Twenty-four hours post-transfection cells were ﬁxed with 4% para-
formaldehyde for 20 min. For Flag-tag staining, cells were gently
permeabilized with 0.5% Tween-20 for 10 min. Fixed cells wereincubated with humanized anti-TL1A (h1B4) (Teva Pharmaceuti-
cals) or anti-Flag Abs overnight followed by incubation with PE-
tagged Goat anti-human IgG or FITC-tagged Goat anti-mouse IgG
(Jackson Laboratories Inc., Bar Harbor, ME) respectively for 1 h.
Coverslips were mounted on glass-slides, using prolong gold
mounting media (Invitrogen, Carlsbad, CA). Slides were imaged
with wide-ﬁeld Nikon microscope (Eclipse TE2000) equipped with
an arc lamp, using Texas-red and FITC ﬁlter cubes with a 40 air
emersion objective.
2.4. Flow cytometry
HEK-293 cells transfected with TL1A-FL, TL1A-M or TL1A-S
expression vectors were incubated with humanized anti-TL1A
(h1B4) or human IgG (Teva Biopharmaceuticals), washed and
stained with FITC-tagged GaHu IgG. Cells were ﬁxed with 1% para-
formaldehyde and analyzed on a ﬂow cytometer (FACScan).
2.5. CD4+ T cells isolation and culture
Blood was obtained from normal donors after informed consent
in accordance with procedures established by the Cedars-Sinai
Institutional Review Board. PBMC were isolated as previously de-
scribed [15]. CD4+ T cells were isolated from PBMC using Human
CD+4 T cell enrichment kit (Stem Cell Technologies, Vancouver,
Canada) and incubated in RPMI complete medium.
2.6. Co-culture of CD4+ T cells with transiently transfected 293 cells
Twenty-four hours after isolation, human IL-12 (ﬁnal concen-
tration, 2 ng/ml; PeproTech) and human IL-18 (ﬁnal concentration
50 ng/ml; R&D systems, Minneapolis, MN) were added to CD4+ T
cells cultured in RPMI complete medium. For TL1A blocking Ab
experiments, a primed CD4+ T cells population was divided into
two and blocking TL1A Ab (h1B4) or hIgG (control), was added at
ﬁnal concentration of 15 lg/ml. CD4+ T cells were then added
(5  105 cells/well) to HEK-293 cells (5  104 cells/well) plated in
24 well dishes that were transiently transfected with TL1A-FL,
TL1A-M, TL1A-S expression vectors or mock transfected with
pIRES-hrGFP 24 h earlier. Recombinant soluble TL1A (Teva Phar-
maceuticals), at ﬁnal concentrations of 2 ng/ml or 20 ng/ml and
cells were co-cultured for 24 h.
2.7. Analysis of TL1A and IFN-c by ELISA
TL1A was quantiﬁed in undiluted supernatants from transfected
HEK-293 cells or from co-cultured experiments, using ELISA as de-
scribed previously [15] with capture mAbs 04H08 or h1B4 and
detector mAb biotinylated-16H02. IFN-c was quantiﬁed by ELISA
as previously reported [12].3. Results
3.1. Generation and characterization of soluble and membrane forms
of TL1A
Migone et al. [1] reported that the N-terminus of soluble TL1A,
puriﬁed from 293T cells transfected with full-length TL1A, was
Leu72. Based on this ﬁnding we designed TL1A-M expression
DNA vectors that lack the putative proteinase cleavage site using
several site-mutations/deletions around Leu72 in full-length
TL1A encoding sequence (Fig. 1C–E). TL1A-FL and modiﬁed TL1A
forms were Flag-tagged downstream (Fig. 2A) or upstream
(Fig. 2B and C). TL1A-S (aa61–251) expression vector included an
upstream Flag-tag and a preprotrypsin leader secretion sequence
Fig. 2. Detection of TL1A expression constructs. (A) HEK-293 cells were transfected with downstream Flag-tagged TL1A expression vectors: (1) empty vector; (2) TL1A-FL; (3)
A71D; (4) D66–75; (5) D66–94 and (6) upstream Flag-tagged TL1A-S. Supernatants were collected for ELISA measurements using anti-Flag coating and 16H02 detection Abs.
Representative of two experiments with similar results. (Inset) Immunoblot of cell lysates using anti-Flag MAb. (B) Comparison of expression of upstream Flag-tagged TL1A
variants in cell lysates (left panel) and supernatants (right panel). Immunoblots were analyzed with 04H08, 16H02 or anti-Flag Abs (C). Supernatants from (B) were measured
by ELISA using 04H08 or h1B4 coating and 16H02 detection Abs. Representative of two experiments with similar results.
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the TL1A expression vectors and collected cells and supernatants
24 h later. Immunoblot analysis of whole cell lysates displayed
TL1A bands of the expected sizes (Fig. 2A, inset). ELISA measure-
ments detected high levels of secreted or processed soluble TL1A
in supernatants of HEK-293 cells transfected with TL1A-S or
TL1A-FL expression vectors (Fig. 2A). Migone et al. [1] has previ-
ously shown that full-length TL1A, transfected in 293T cells, can
be processed without addition of external proteinases. Out of the
three mutated TL1A forms ﬂanking Leu72, only aa66–94 deletion
resulted in loss of detectable TL1A in the supernatant. Expression
of non-cleavable TL1A-M was further conﬁrmed by immunoblot
comparing protein expression in the cell lysate to that within the
supernatant (Fig. 2B). Two monoclonal anti-TL1A antibodies
against distinct epitopes, 04H08 and 16H02, were utilized. Both
MAb detected expression of full-length, membrane-bound and se-
creted forms of TL1A within the cell lysates. Supernatant from
TL1A-FL expressing cells exhibited a weak but detectable lower
molecular weight band indicating a cleaved soluble TL1A form
(Fig. 2B). In contrast, no band was seen for TL1A-M. TL1A expres-
sion in the supernatants was also measured by ELISA using
04H08 or the humanized TL1A antibody h1B4 for capture and
16H02 for detection (Fig. 2C). h1B4 could not be used for immuno-
blotting as it does not recognize denatured TL1A (data not shown).
Although expression of TL1A-FL and TL1A-S were detected by both
antibody combinations, no combination of antibodies was able to
detect secreted TL1A in the supernatant of cells transfected with
TL1A-M.
The presence of TL1A-M at the plasma membrane was further
veriﬁed by surface staining using immuno-histochemistry and
FACS analysis (Fig. 3). As expected, TL1A-FL demonstrated location
at the plasma membrane (Fig. 3A and B, top panels). Expression of
TL1A-M (Fig. 3A and B, middle panels) was likewise detected by
surface staining. In cells expressing TL1A-S, only dim vesicles were
observed indicating the exocytosis process (Fig. 3A, lower left pa-
nel) which was likewise detected by FACS analysis as staining withweak ﬂorescent intensity (Fig. 3C). All three TL1A forms were
shown to be expressed in cells when permeabilized and detected
for Flag (Fig. 3A, right panel).
3.2. TL1A-M binds DR3
TL1A-FL and TL1A-S (aa72–251) were shown to bind DR3 as
well as TR6 [1]. To verify that TL1A-M, expressed in HEK-293 cells,
is capable of binding the receptor, TL1A-M, TL1A-FL and TL1A-S,
expressed in HEK-293 cells, were incubated with recombinant
Fc-tagged extracellular domain of DR3 (DR3-Fc). DR3-Fc was pre-
cipitated and samples were immunoblotted using anti-Flag Ab.
As shown in Fig. 4, TL1A-M, like TL1A-S and TL1A-FL, bound to
DR3-Fc, indicating that deletion of amino acids 66–94 did not dis-
turb the binding between DR3 and TL1A-M.
3.3. TL1A-M enhances IFN-c production by CD4+ T cells
Meylan et al. [5] reported that DR3 is expressed primarily on T
cells with the highest expression on CD4+ T cells. In order to deter-
mine whether TL1A-M can activate DR3 and induce downstream
signaling, we tested the functional effect of TL1A-M on CD4+ T cells.
We used an IL-12/L-18-primed CD4+ T cell culture system previ-
ously described by our group [15,23] in which IFN-c production
by CD4+ T cells is measured as an end point. TL1A has shown to
potentiate secretion of IFN-c in this system. The levels of secreted
IFN-c in response to TL1A-M were compared to those in response
to TL1A-FL, TL1A-S and mock transfected cells. As shown in Fig. 5A
we observed a statistically signiﬁcant increase of 3-fold in IFN-c
production by IL-12/IL-18-primed CD4+ T cells co-cultured with
TL1A-M expressing HEK-293 cells compared with mock transfec-
ted cells (P value 6 0.04). Moreover, IFN-c enhancement in re-
sponse to TL1A-M displayed 50% of the activity of that induced
by TL1A-FL, which exhibits both soluble ad membrane-bound
expression (Fig. 2). A further 2–5-fold enhancement was detected
for TL1A-S, compared to TL1A-FL and TL1A-M respectively
Fig. 3. Surface expression of TL1A constructs. (A) Representative Immunohistochemical images of expressed upstream Flag-tagged TL1A-FL, TL1A-M or TL1A-S. Surface TL1A
was detected with h1B4 (no permeabilization). Total cell TL1A was with anti-Flag (after permeabilization). PE-tagged GaHu or FITC-tagged GaM IgG were used for
visualization. (B) Flow cytometry plots of 293 cells expressing TL1A-FL, TL1A-M or TL1A-S. Surface TL1A was detected with h1B4 (complete line with gray background) or
hIgG as negative control (dotted line no background). (C) Mean ﬂuorescent intensities of ﬂow cytometry data from (B).
Fig. 4. Binding of the different TL1A forms to recombinant DR3-Fc. HEK-293 cells
were transfected with upstream Flag-tagged TL1A-FL (2), TL1A-M (3) or TL1A-S (4)
expressing vectors or with an empty vector (1). Cells were lysed and incubated with
recombinant Fc-tagged extracellular domain of DR3 (rDR3-Fc) and TrueBlot beads.
Proteins, released from the beads were loaded onto SDS-PAGE and analyzed using
MFb against Flag.
Fig. 5. TL1A-M functionally enhances IFN-c secretion. (A) HEK-293 cells transfected wi
vector alone, were co-incubated for 24 h with IL-12/IL-18 primed CD4+ T cells. Supernatan
experiments with similar results. (B) Cells transfected with TL1A-M or mock transfected
TL1A Ab (h1B4) or hIgG isotype control. To functionally quantify the effects of TL1A-M
concentrations of 0, 2 or 20 ng/ml and IFN-c levels were measured using ELISA. Represe
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TL1A-M we compared the effect of TL1A-M to increasing amounts
of recombinant TL1A added to mock transfected HEK-293 cells co-
cultured with primed T cells (Fig. 5B). The magnitude of IFN-c
enhancement in response to TL1A-M was comparable to 2 ng/ml
recombinant TL1A. To conﬁrm that the enhancement in IFN-c pro-
duction was in response to TL1A, TL1A blocking Ab (h1B4) or con-
trol hIgG were added to the co-culture. Enhanced IFN-c production
was a result of TL1A signaling as TL1A blocking Ab inhibited the in-
crease in IFN-c (Fig. 5B black bars). These results indicate that
membrane bound TL1A function similarly as soluble TL1A in induc-
tion of IFN-c production by CD4+ T cells.th TL1A-FL, TL1A-S or TL1A-M expressing vectors or mock transfected with empty
ts were collected and IFN-c levels were measured by ELISA. Representative of three
were co-incubated with primed-CD4+ T cells as above in the presence of blocking
, in parallel recombinant TL1A (aa72–251) was added to mock samples at ﬁnal
ntative of three experiments with similar results.
Table 1
Results summary.
Cell surface Soluble Functional
TL1A-FL + + ++
TL1A-S  + +++
TL1A-M +  +
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Although studied intensively in the recent years, most of our
knowledge about TL1A structure and function has been established
mainly through its soluble form. Since it is not yet known what
proteinase cleaves membrane TL1A into its soluble form, TL1A-S
effect could not be eliminated, to enable investigating the potential
effect of membrane-bound TL1A.
In this study we created a membrane-bound TL1A expressing
vector by removing aa66–94 from full-length TL1A (Figs. 2 and
3). Interestingly, out of the three modiﬁcations done around the
potential cleavage site, only TL1A (D66–94) generated a non-cleav-
able membrane-bound product. Single mutation at Ala71, as well
as deletion of aa66–75, did not prevent TL1A cleavage. These re-
sults might suggest a proteinase with wide substrate recognition
or the possibility of another cleavage site close by, other then be-
tween Ala71 and Leu72.
We further demonstrated that TL1A-M was capable of binding
DR3 (Fig. 4) and inducing immune response through CD4+ T cells
(Fig. 4). We observed a statistically signiﬁcant 3-fold increase of
IFN-c production in response to TL1A-M compared to mock, which
was approximately 50% of that observed in response to TL1A-FL.
This increase is similar to our observation in earlier studies with
IL-12/IL-18-primed CCR9+ CD4+ T cells [13]. A further enhance-
ment of IFN-c production is induced by TL1A-S. The results are
summarized in Table 1. The difference in IFN-c enhancement be-
tween the different TL1A forms was expected, since the current
setup is not optimal for cell–cell contact-mediated signaling re-
quired for membrane-bound TL1A. There are several limitations
in this setup: (1) only a fraction of transfected HEK-293 cells ex-
press the transcript, (2) only a subset of CD4+T cells population re-
sponds to TL1A, and (3) 293 cells are adherent cells thus the effect
of TL1A-M, which occur thorough cell–cell contact, is spatially lim-
ited to a monolayer. However, we did observe that reducing the
reaction volume, as well as increasing CD4+ T cells concentration,
did increase TL1A-M effect (data not shown). Despite these limita-
tions the enhancement in IFN-cwas conﬁrmed to be in response to
TL1A presence, since TL1A blocking Ab inhibited IFN-c increase.
The effect of TL1A-M on IFN-c enhancement was comparable to
2 ng/ml recombinant TL1A, which is within the range of TL1A
expression observed in supernatants of IC-stimulated monocytes
[15].
In earlier studies we observed differential TL1A expression be-
tween the different immune cells. APC demonstrated both mem-
brane-bound and soluble TL1A when induced by IC [15] or by
microbial organisms [17]. However, TLIA expression in T cells,
was found only at the membrane and it has been shown to func-
tion in increased IL-12/IL-18 induced IFN-c production in CCR9+
CD4+ cells [12,13]. This suggests that T cells expressing mem-
brane-bound TL1A come in contact with T cells expressing mem-
brane DR3 to induce increased IFN-c production. The results in
this study demonstrate the likelihood of this scenario.
Studies in mouse models, using neutralizing TL1A antibody,
have shown to signiﬁcantly attenuate chronic colitis [8] and pro-
tect against systemic rheumatoid arthritis [2]. In these studies
TL1A antibody was designed to recognize and block soluble recom-
binant TL1A. Only a partial recovery of inﬂamed tissue in response
to TL1A antibody was observed in both studies. Given that bothmembrane and soluble TL1A are functionally competent, antibod-
ies designed to block TL1A function to prevent/treat immune med-
iated diseases, should be veriﬁed to recognize and block both forms
of endogenous TL1A functions, not just the recombinant form.
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